Blueprint Medicines Completes Acquisition of Lengo Therapeutics

Expands Blueprint Medicines' lung cancer pipeline with LNG-451, a highly selective brain-penetrant precision therapy targeting EGFR exon 20 insertion mutations Investigational New Drug application for LNG-451 submitted to U.S. FDA by Lengo Therapeutics ... Biopharmaceuticals, Mergers & Acquisitions Blueprint Medicines, Lengo Therapeutics, precision therapy, NSCLC
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news